Li Weiwei, Luo Shunxiang, Ma Guowei, Wang Lin
Department of Oncology, The First People's Hospital of Tianmen City, Hubei, China.
Department of Gastrointestinal Surgery, The First People's Hospital of Tianmen City, Hubei, China.
Onco Targets Ther. 2019 Feb 22;12:1439-1445. doi: 10.2147/OTT.S199138. eCollection 2019.
Liver kinase B1 (LKB1) is a newly discovered tumor suppressor gene that plays a role in apoptosis induction. However, the precise impact of LKB1 expression on gastric cancer (GC) progression and its correlation with survivin and p53 in GC have not yet been elucidated.
The aim of this study was to explore the significance of LKB1 expression and its correlation with p53 and survivin in GC.
In this study, LKB1 expression was detected in GC and adjacent paracancerous tissues from 150 patients through immunohistochemical (IHC) staining. The relationship between LKB1 expression and clinical pathological factors in GC was analyzed, alongside its correlation with p53 and survivin expression.
LKB1 expression was reduced in GC tissues compared with adjacent paracancerous tissues (=0.001). In patients with GC, lower LKB1 expression was associated with greater invasion depth (=0.013), higher pTNM stage (=0.009), and lymph node metastasis (=0.029). Furthermore, LKB1 expression in GC was inversely associated with p53 (=-0.181, =0.027) and survivin expression (=-0.198, =0.015). Kaplan-Meier analysis indicated that the expression of LKB1, p53 and survivin, as well as tumor differentiation, invasion, and pTNM and lymph node metastasis were all associated with overall survival (OS) (all <0.05). Finally, multivariate analysis showed that LKB1 expression [hazard ratio (HR): 0.605 (0.414-0.882), =0.009], p53 expression [hazard ratio (HR): 1.840 (1.232-2.750), =0.003], and survivin expression [hazard ratio (HR): 1.561 (1.039-2.345), =0.032] were all independent prognostic factors for patients with GC.
Our study suggests that LKB1 expression is reduced in GC, negatively correlated with p53 and survivin expression, and plays an important role in predicting invasion and metastasis of GC.
肝脏激酶B1(LKB1)是一种新发现的肿瘤抑制基因,在诱导细胞凋亡中发挥作用。然而,LKB1表达对胃癌(GC)进展的精确影响及其与GC中生存素和p53的相关性尚未阐明。
本研究旨在探讨LKB1表达在GC中的意义及其与p53和生存素的相关性。
在本研究中,通过免疫组织化学(IHC)染色检测了150例患者的GC组织及癌旁组织中LKB1的表达。分析了LKB1表达与GC临床病理因素之间的关系,以及其与p53和生存素表达的相关性。
与癌旁组织相比,GC组织中LKB1表达降低(=0.001)。在GC患者中,较低的LKB1表达与更大的浸润深度(=0.013)、更高的pTNM分期(=0.009)和淋巴结转移(=0.029)相关。此外,GC中LKB1表达与p53(=-0.181,=0.027)和生存素表达(=-0.198,=0.015)呈负相关。Kaplan-Meier分析表明,LKB1、p53和生存素的表达以及肿瘤分化、浸润、pTNM和淋巴结转移均与总生存期(OS)相关(均<0.05)。最后,多因素分析显示,LKB1表达[风险比(HR):0.605(0.414 - 0.882),=0.009]、p53表达[风险比(HR):1.840(1.232 - 2.750),=0.003]和生存素表达[风险比(HR):1.561(1.039 - 2.345),=0.032]均为GC患者的独立预后因素。
我们的研究表明,GC中LKB1表达降低,与p53和生存素表达呈负相关,在预测GC的侵袭和转移中起重要作用。